2. Academic Validation
  3. Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)

Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)

  • J Med Chem. 2018 Dec 27;61(24):11021-11036. doi: 10.1021/acs.jmedchem.8b01291.
Atwood K Cheung 1,  Brian Hurley 1,  Ryan Kerrigan 1,  Lei Shu 1,  Donovan N Chin 1,  Yiping Shen 1,  Gary O'Brien 1,  Moo Je Sung 1,  Ying Hou 1,  Jake Axford 1,  Emma Cody 1,  Robert Sun 1,  Aleem Fazal 1,  Cary Fridrich 1,  Carina C Sanchez 1,  Ronald C Tomlinson 1,  Monish Jain 1,  Lin Deng 1,  Keith Hoffmaster 1,  Cheng Song 1,  Mailin Van Hoosear 1,  Youngah Shin 1,  Rebecca Servais 1,  Christopher Towler 2,  Marc Hild 1,  Daniel Curtis 1,  William F Dietrich 1,  Lawrence G Hamann 1,  Karin Briner 1,  Karen S Chen 3,  Dione Kobayashi 3,  Rajeev Sivasankaran 1,  Natalie A Dales 1
Affiliations

Affiliations

  • 1 Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue , Cambridge , Massachusetts 02139 , United States.
  • 2 Novartis Pharmaceuticals , 250 Massachusetts Avenue , Cambridge , Massachusetts 02139 , United States.
  • 3 SMA Foundation , 888 Seventh Avenue, Suite 400 , New York , New York 10019 , United States.
PMID: 30407821 DOI: 10.1021/acs.jmedchem.8b01291
Abstract

Spinal muscular atrophy (SMA), a rare neuromuscular disorder, is the leading genetic cause of death in infants and toddlers. SMA is caused by the deletion or a loss of function mutation of the survival motor neuron 1 (SMN1) gene. In humans, a second closely related gene SMN2 exists; however it codes for a less stable SMN protein. In recent years, significant progress has been made toward disease modifying treatments for SMA by modulating SMN2 pre-mRNA splicing. Herein, we describe the discovery of LMI070/branaplam, a small molecule that stabilizes the interaction between the spliceosome and SMN2 pre-mRNA. Branaplam (1) originated from a high-throughput phenotypic screening hit, pyridazine 2, and evolved via multiparameter lead optimization. In a severe mouse SMA model, branaplam treatment increased full-length SMN RNA and protein levels, and extended survival. Currently, branaplam is in clinical studies for SMA.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z